{
    "clinical_study": {
        "@rank": "94085", 
        "arm_group": [
            {
                "arm_group_label": "MT-1303-Low", 
                "arm_group_type": "Experimental", 
                "description": "MT-1303-Low Dose"
            }, 
            {
                "arm_group_label": "MT-1303-Middle", 
                "arm_group_type": "Experimental", 
                "description": "MT-1303-Middle Dose"
            }, 
            {
                "arm_group_label": "MT-1303-High", 
                "arm_group_type": "Experimental", 
                "description": "MT-1303-High Dose"
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate the long-term safety and tolerability of MT-1303 in subjects with relapsing\n      remitting multiple sclerosis (RRMS)."
        }, 
        "brief_title": "Extension Study of MT-1303", 
        "completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Relapsing-remitting Multiple Sclerosis", 
        "condition_browse": {
            "mesh_term": [
                "Multiple Sclerosis", 
                "Sclerosis", 
                "Multiple Sclerosis, Relapsing-Remitting"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Completion of the 24-week treatment period in MT-1303-E04 as per protocol\n\n          -  Able to provide written informed consent and to comply with the requirements of the\n             protocol\n\n          -  For males and females of reproductive potential, two methods of contraception must be\n             used throughout the study and for 12 weeks after cessation of study medication. At\n             least one of the methods of contraception must be a barrier method.\n\n        Exclusion Criteria:\n\n          -  Permanent discontinuation of study medication prior to the end of treatment (EOT)\n             visit in MT-1303-E04\n\n          -  Newly diagnosed diabetes mellitus during MT-1303-E04"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "400", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01890655", 
            "org_study_id": "MT-1303-E05"
        }, 
        "intervention": [
            {
                "arm_group_label": "MT-1303-Low", 
                "intervention_name": "MT-1303-Low", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "MT-1303-Middle", 
                "intervention_name": "MT-1303-Middle", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "MT-1303-High", 
                "intervention_name": "MT-1303-High", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "relapsing-remitting multiple sclerosis", 
            "RRMS"
        ], 
        "lastchanged_date": "March 11, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Berlin", 
                        "country": "Germany"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Roma", 
                        "country": "Italy"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Research Site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Canada", 
                "Germany", 
                "Italy", 
                "Spain", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase II, Multicentre Study to Evaluate the Long-term Safety and Efficacy of MT-1303 in Subjects With Relapsing-remitting Multiple Sclerosis Who Have Completed the MT-1303-E04 Study", 
        "overall_contact": {
            "email": "cti-inq-ml@ml.mt-pharma.co.jp", 
            "last_name": "Clinical Trials Information Desk"
        }, 
        "overall_official": {
            "affiliation": "University Hospital, Basel, Switzerland", 
            "last_name": "Ludwig Kappos, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Canada: Health Canada", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Adverse Events", 
            "measure": "Safety assessments", 
            "safety_issue": "Yes", 
            "time_frame": "Month 18"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01890655"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Annualised relapse rate(ARR)", 
                "measure": "Clinical efficacy", 
                "safety_issue": "No", 
                "time_frame": "Month 18"
            }, 
            {
                "description": "Change and percent change in brain volume at EOT", 
                "measure": "Magnetic Resonance Imaging (MRI)", 
                "safety_issue": "No", 
                "time_frame": "Month 18"
            }
        ], 
        "source": "Mitsubishi Tanabe Pharma Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mitsubishi Tanabe Pharma Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}